Text Size

Retinitis Pigmentosa: Burden of Disease and Current Unmet Needs

Cross N, van Steen C, Zegaoui Y, Satherley A, Angelillo L


  • 2022
  • Clinical Ophthalmology
View publication
  • Therapeutic Area

    Back of the eye (BOTE)

  • Categories

    Disease understanding (epidemiology, diagnosis, QoL, Biomarkers…)

  • Affiliations

    Market Access, Lightning Health, London, England, UK; Market Access HTA & HEOR, EMEA, Santen GmbH, Munich, Bavaria, Germany

Related Publications

Cost-Effectiveness Analysis of Low-Dose Atropine Eye Drops (0.01%) for the Treatment of Myopia in Children: A United Kingdom Perspective

Shi-van Wielink K., Dahlmann-Noor A., Li J., de Milliano T.W.L., Ernst F., Croci F., Sharma Y., Punekar Y.


Two-year prospective natural history study of EYS-associated retinitis pigmentosa using adaptive optics: the KEYS study

Masakazu H., Akiko M., Midori Y., Elena G.-S., Shohei K., Satoshi Y., Yuki T., Masanao T., Shuhei K., Yasuhiko H., Yasuo K., Kiyoko G.


Prospective natural history and clinical biomarkers of EYS-associated retinopathy in the KEYS study

Taniguchi M, Togashi Y, Yokota S, Hiraoka M, Kitahata S, Nakamura N, Yamamoto M, Mandai M, Gocho K, Toshimori M, Hirami Y, Gomi F, Kurimoto Y, Maeda A.


Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022